ClinicalTrials.gg
RecruitingNCT06345963Updated Jul 7, 2026

Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)

An interventional study of active H-coil delivered rTMS in Schizophrenia, sponsored by The University of Texas Health Science Center, Houston. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by The University of Texas Health Science Center, Houston · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Schizophrenia by The University of Texas Health Science Center, Houston — 8 open to participants now, 8 under way, none of them phase 3. Schizophrenia · The University of Texas Health Science Center, Houston.

Planned enrollment
2nd of 11
120 · median 120
Started
2024
the only one that year
No phase
10 of 11
8 open now
Registered
6th of 11
by date

Among the 11 studies in Schizophrenia by The University of Texas Health Science Center, Houston, this one is the 2nd largest by planned enrollment, is the only one that started in 2024, is one of 10 with no phase, and was the 6th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

8 of the 11 studies in Schizophrenia by The University of Texas Health Science Center, Houston are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Schizophrenia by The University of Texas Health Science Center, Houston, or all of them as a file.
02

Study summary

Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from H coil for improving white matter integrity.

Read the detailed description

Schizophrenia is a severe mental illness that affects about 1% of the population but a major source of disability. Information processing between brain regions occurs due to transfer of electrical impulses among them. This process is determined by the existing neuronal/fiber connections, which may be altered and or modified in the presence of neuronal stimulation or cognitive intervention. The frontal lobe information flow is critical for higher cognitive functions, thought processes, and proper emotional and behavioral responses. Improving the myelination in the frontal lobe may increase cognitive functions and reduce risks to develop symptoms of schizophrenia. The investigators propose that increasing electrical signaling in the frontal white matter in patients with schizophrenia may also enhance myelination and improve the white matter integrity.

The patients with schizophrenia will receive active repetitive transcranial magnetic stimulation (rTMS) treatment. The rTMS with H coil is FDA-cleared for short-term smoking cessation in the general population. Its efficacy in myelination modulation has not been evaluated.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Transcranial magnetic stimulation
  • schizophrenia
  • white matter
  • connectivity
  • myelination
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female ages between ages 18-60 years
  2. Ability to give written (age 18 or above)
  3. Diagnosed with schizophrenia-spectrum disorder and Evaluation to Sign Consent (ESC) above 10.

Exclusion criteria

Exclusion Criteria:

  1. Inability to sign .
  2. Any history of seizures.
  3. Any acute and unstable major medical illnesses that may affect normal brain functioning. Examples of these conditions include, but not limited to, recent stroke, seizure, history of significant head trauma, CNS infection or tumor, other significant brain neurological conditions (As this is a study of medical comorbidity, most medical conditions, once stable, are not exclusion criteria).
  4. Taking > 400 mg clozapine/day.
  5. Failed TMS screening questionnaire.
  6. Significant alcohol or other drug use (substance dependence within 6 months or substance abuse within 1 month) other than nicotine or marijuana dependence.
  7. A history of thrombosis, family history of thrombosis, or medical conditions that may lead to a hypercoagulable state (increased chance to develop blood clots)
  8. Woman who is pregnant ( but not on and missing menstrual period; or by self-report; or by positive urine pregnancy test).
  9. History of head injury with loss of consciousness over 10 minutes; history of brain surgery
  10. Cannot refrain from using alcohol and/or marijuana 24 hours or more prior to experiments.
  11. Students and employees currently involved with our lab (lab employees and personnel will be excluded from the study to avoid possible coercion or possible appearance of coercion, or chance of breach of privacy and confidentiality).
  12. For MRI, unable to undergo MRI scanning due to metallic devices or objects (cardiac pacemaker or neurostimulator, some artificial joints, metal pins, surgical clips, or other implanted metal parts) or claustrophobic to the scanner.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Active rTMS

    Participants in this group will receive active H-coil delivered rTMS.

    Device: active H-coil delivered rTMS

Interventions

  • Deviceactive H-coil delivered rTMS

    Multiple trains of rTMS in a day, for multiple days.

06

What researchers measure

Primary outcomes

  1. Brain microstructural integrity as indicated by white matter fractional anisotropy (FA) values as assessed by magnetic resonance imaging (MRI)

    Fractional anisotropy (FA) values will be reported. FA values range from 0 to 1 with larger values indicating greater white matter integrity.

    Time frame: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)

  2. Brain connectivity as indicated by resting-state functional connectivity (rsFC) values as assessed by functional MRI (fMRI)

    rsFC values will be reported as a Z-score with a range of -1 to 1, with greater absolute values indicating stronger brain connectivity.

    Time frame: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)

Secondary outcomes

  1. Electrophysiological response as indicated by mismatch negativity as assessed by electroencephalography (EEG)

    Mismatch negativity values will be reported in microvolts (uV). Mismatch negativity is measured by subtracting the averaged response to a set of standard stimuli from the average response to deviant stimuli, and taking the amplitude of this difference in a given timepoint.

    Time frame: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)

  2. Electrophysiological response as indicated by steady-state auditory evoked responses from electroencephalography recording (EEG)

    Steady-state auditory evoked responses will be reported. The responses are measured by calculating the ratio of the power at target frequency over power at the surrounding background frequencies. The ration will be obtained in a given timepoint.

    Time frame: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)

  3. Cognitive insight as assessed by the Beck Cognitive Insight Scale

    Total score will be reported and ranges from 15 to 60, with a higher score indicating greater cognitive insight.

    Time frame: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)

  4. Depression as assessed by the Depression State and Trait Scale (DST) - state

    Total score of the state subscale of the DST will be reported and ranges from 0 to 72, with a higher score indicating greater depression state.

    Time frame: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)

  5. Depression as assessed by the Depression State and Trait Scale (DST) - trait

    Total score of the trait subscale of the DST will be reported and ranges from 0 to 72, with a higher score indicating greater depression trait.

    Time frame: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)

  6. Depression as assessed by the Calgary Depression Scale

    Total score of the Calgary Depression Scale will be reported and ranges from 0 to 27, with a higher score indicating greater depression.

    Time frame: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)

  7. Depression as assessed by the Beck Depression Inventory

    Total score of the Beck Depression Inventory will be reported and ranges from 0 to 63, with a higher score indicating greater depression.

    Time frame: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)

  8. Perception as assessed by the Perception State and Trait Scale - state

    The Perception State and Trait Scale assesses alterations in the perception of audio and visual experiences. Total score ranges from 0 to 96 for the state subscale, and a higher score indicates a greater alteration of audio or visual experiences state.

    Time frame: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)

  9. Perception as assessed by the Perception State and Trait Scale - trait

    The Perception State and Trait Scale assesses alterations in the perception of audio and visual experiences. Total score ranges from 0 to 96 for the trait subscale, and a higher score indicates a greater alteration of audio or visual experiences trait.

    Time frame: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)

  10. Delusion as assessed by the 21-item Peters Delusion Inventory (PDI-21)

    Total score will be reported and ranges from 0 to 21, with a higher score indicating greater delusion.

    Time frame: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)

  11. Emotion regulation as assessed by the Profile of Mood States (POMS)

    Total score will be reported and ranges from 0 to 204, with a higher score indicating more positive emotion and mood. This outcome measure will be assessed at each of the 10 treatment visits (which are about day 1 after baseline, day 2 after baseline, day 3 after baseline, day 4 after baseline, day 5 after baseline, day 9 after baseline, day 10 after baseline, respectively).

    Time frame: day 1 after baseline, day 2 after baseline, day 3 after baseline, day 4 after baseline, day 5 after baseline, day 9 after baseline, day 10 after baseline

  12. Hallucination as assessed by the Revised Hallucinations Scale (RHS)

    Total score will be reported and ranges from 0 to 13, with a higher score indicating greater hallucination. This outcome measure will be assessed at each of the 10 treatment visits (which are about day 1 after baseline, day 2 after baseline, day 3 after baseline, day 4 after baseline, day 5 after baseline, day 9 after baseline, day 10 after baseline, respectively).

    Time frame: day 1 after baseline, day 2 after baseline, day 3 after baseline, day 4 after baseline, day 5 after baseline, day 9 after baseline, day 10 after baseline

  13. Cognitive function as assessed by the Letter-Number Span subscale of the MATRICS consensus cognitive battery (MCCB)

    Total score will be reported and ranges from 0 to 24, with a higher score indicating greater cognitive function.

    Time frame: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)

  14. Cognitive function as assessed by the Spatial Span subscale of the MATRICS consensus cognitive battery (MCCB)

    Total score will be reported and ranges from 0 to 32, with a higher score indicating greater cognitive function.

    Time frame: baseline, visit 6 (about 1 week after baseline), visit 10 (about 2 weeks after baseline)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for May 2029, 59 months after the start.

Of 763 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 59 months is above that.

Counting every sponsor, half of 776 studies reached it within 32 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2024
First posted
Apr 3, 2024
StartActual
May 21, 2024
Primary completionEst.
May 1, 2029
CompletionEst.
May 1, 2030
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06345963
Responsible party
Xiaoming Du (Assistant Professor, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Apr 3, 2024
Start date
May 21, 2024
Primary completion
May 1, 2029 (estimated)
Completion
May 1, 2030 (estimated)
Last update
Jul 7, 2026

Study contacts

Victoria M Acosta
Contact
Victoria.Acosta@uth.tmc.edu
713-486-2740
Xiaoming Du, PhD
Contact
Xiaoming.Du@uth.tmc.edu
443-882-9717
Xiaoming Du, PhD
principal investigator · The University of Texas Health Science Center, Houston

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion